Choosing neoadjuvant therapy for muscle-invasive bladder cancer based on efficacy-safety trade-off: a network meta-analysis
Zilin Zhao, Xinyu Liu, Qikai Zhong, Lin Liu, Runze Pan, Junzhi Chen, Xinlei Wang, Xing Liu, Jiangshang Bao, Yufeng Sun, Conghui Han, Zhenduo Shi, Qing Liang · 2026
Read Choosing neoadjuvant therapy for muscle-invasive bladder cancer based on efficacy-safety trade-off: a network meta-analysis by Zilin Zhao, Xinyu Liu, Qikai Zhong, Lin Liu, Runze Pan, Junzhi Chen, Xinlei Wang, Xing Liu, Jiangshang Bao, Yufeng Sun, Conghui Han, Zhenduo Shi, Qing Liang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13306761.txt.
Description
Zilin Zhao compared pre-surgery treatments for muscle-invasive bladder cancer in a 2026 network meta-analysis. Fourteen studies with 2234 patients weighed combined chemo-immunotherapy against chemotherapy alone and immune therapy alone before bladder surgery.
Full tumour clearance at surgery was highest for the combined route at 0.41 in pooled figures, ahead of immune therapy at 0.26 and chemotherapy at 0.15 in the reported rates. Network odds strongly favoured the combination over chemotherapy alone. Severe side effects ran highest in the chemotherapy group in early results, shaping the efficacy and safety trade-off. Care teams can use the trade off to pick a plan that fits each case.
Catalog record
| CREATOR | Zilin Zhao, Xinyu Liu, Qikai Zhong, Lin Liu, Runze Pan, Junzhi Chen, Xinlei Wang, Xing Liu, Jiangshang Bao, Yufeng Sun, Conghui Han, Zhenduo Shi, Qing Liang |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 30419 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |